RGNX · REGENXBIO Inc. · Webcasts, Transcripts & Audio
$7.64
-0.39 (-4.86%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Going-concern doubt
— flagged Nov 5, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about our ability to continue as a going concern within 12 months from the issuance date of our consolidated financial statements for the three and nine months ended September 30, 2026 included in this Quarterly Report on Form 10-Q.”View the 10-Q filed Nov 5, 2026
Market Cap
$505.18M
Shares
66.12M
Volume · Nov 13
716.16K
Avg daily vol (3M)
1.39M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
REGENXBIO Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for REGENXBIO Inc. (RGNX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-11
REGENXBIO Inc. (RGNX) November 11, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-05
REGENXBIO Inc. (RGNX) Q3 2026 Earnings Call Transcript
Confident tone
RGX202 BLA and potential approval
Wet AMD pivotal data and regulatory milestones
Duchenne efficacy and product differentiation
Revenue
$9.16M
▼ 69.2% YoY Diluted EPS
$-0.62
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-16
REGENXBIO Inc. (RGNX) September 16, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-16
REGENXBIO Inc. (RGNX) September 16, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-15
REGENXBIO Inc. (RGNX) September 15, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-15
REGENXBIO Inc. (RGNX) September 15, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-06
REGENXBIO Inc. (RGNX) Q2 2026 Earnings Call Transcript
Confident tone
RGX-202 Duchenne gene therapy program
ABBVIE / Curovec retinal collaboration
RGX-121 Hunter syndrome regulatory progress
Revenue
$108.02M
▲ 405.7% YoY Diluted EPS
$0.43
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-05-20
REGENXBIO Inc. (RGNX) May 20, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-20
REGENXBIO Inc. (RGNX) May 20, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-14
REGENXBIO Inc. (RGNX) Q1 2026 Earnings Call Transcript
Confident tone
RGX-202 pivotal Phase III data
Microdystrophin expression and functional correlation
Approval pathway and regulatory strategy
Revenue
$6.39M
▼ 92.8% YoY Diluted EPS
$-1.72
▼ 1533.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-05
REGENXBIO Inc. (RGNX) Q4 2025 Earnings Call Transcript
Positive tone
RGX202 Duchenne gene therapy
AbbVie partnership and Navigate in diabetic retinopathy
Regulatory pathway and FDA engagement
Revenue
$30.34M*
▲ 43% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
REGENXBIO Inc. (RGNX) Q3 2025 Earnings Call Transcript
Confident tone
RGX-202 Duchenne pivotal trial and BLA
Subretinal sura-vec for wet AMD (AbbVie)
RGX-121 MPS II BLA and approval
Revenue
$29.73M
▲ 22.9% YoY Diluted EPS
$-1.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
REGENXBIO Inc. (RGNX) Q2 2025 Earnings Call
Revenue
$21.36M
▼ 4.2% YoY Diluted EPS
$-1.38
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
REGENXBIO Inc. (RGNX) Q1 2025 Earnings Call Transcript
Confident tone
RGX-202 Duchenne Pivotal Program
Retinal Programs / ABBV-RGX-314 Partnership
RGX-121 / Hunter Syndrome Regulatory Progress
Revenue
$89.01M
▲ 469.8% YoY Diluted EPS
$0.12
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-13
REGENXBIO Inc. (RGNX) Q4 2024 Earnings Call Transcript
Confident tone
RGX-202 Duchenne muscular dystrophy pivotal program
Regulatory milestones and FDA interactions
Clinical data readouts (biomarker and functional)
Revenue
$21.21M*
▼ 4.5% YoY Gross margin
70.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript
Confident tone
RGX-202 Duchenne program
RGX-314 retinal franchise with AbbVie
RGX-121 MPS II / Hunter syndrome BLA
Revenue
$24.20M
▼ 16.3% YoY Diluted EPS
$-1.17
Gross margin
48.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
REGENXBIO Inc. (RGNX) Q2 2024 Earnings Call Transcript
Confident tone
AbbVie RGX-314 retinal programs
RGX-202 Duchenne gene therapy
Fellow Eye study and immune response
Revenue
$22.30M
▲ 11.6% YoY Diluted EPS
$-1.05
Gross margin
52.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
REGENXBIO Inc. (RGNX) Q1 2024 Earnings Call Transcript
Confident tone
RGX-202 Duchenne program and pivotal dose
Diabetic retinopathy suprachoroidal pivotal plans
RGX-314 AbbVie collaboration
Revenue
$15.62M
▼ 18.4% YoY Diluted EPS
$-1.38
Gross margin
72.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
REGENXBIO Inc. (RGNX) Q4 2023 Earnings Call Transcript
Confident tone
RGX-202 Duchenne Program
AbbVie Partnership Milestones
RGX-121 / MPS II (Hunter Syndrome)
Revenue
$22.21M*
▼ 29.1% YoY Gross margin
49.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
REGENXBIO Inc. (RGNX) Q3 2023 Earnings Call Transcript
Revenue
$28.91M
▲ 9.1% YoY Diluted EPS
$-1.41
Gross margin
57.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
REGENXBIO Inc. (RGNX) Q2 2023 Earnings Call Transcript
Revenue
$19.98M
▼ 38.8% YoY Diluted EPS
$-1.66
Gross margin
52.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
REGENXBIO Inc. (RGNX) Q1 2023 Earnings Call Transcript
Revenue
$19.14M
▼ 13.9% YoY Diluted EPS
$-1.53
Gross margin
78.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
REGENXBIO Inc. (RGNX) Q4 2022 Earnings Call Transcript
Revenue
$31.34M*
▼ 92.1% YoY Gross margin
59.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
REGENXBIO Inc. (RGNX) Q3 2022 Earnings Call Transcript
Revenue
$26.51M
▼ 13.8% YoY Diluted EPS
$-1.75
Gross margin
50.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
REGENXBIO Inc. (RGNX) Q2 2022 Earnings Call Transcript
Revenue
$32.65M
▲ 48.2% YoY Diluted EPS
$-1.58
Gross margin
60.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
REGENXBIO Inc. (RGNX) Q1 2022 Earnings Call Transcript
Revenue
$22.22M
▲ 17.7% YoY Diluted EPS
$-1.79
Gross margin
29.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
REGENXBIO Inc. (RGNX) Q4 2021 Earnings Call Transcript
Revenue
$398.65M*
▲ 1759% YoY Gross margin
94.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-02
REGENXBIO Inc. (RGNX) Q3 2021 Earnings Call Transcript
Revenue
$30.77M
▼ 68.9% YoY Diluted EPS
$-1.37
▼ 695.7% YoY Gross margin
54.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
REGENXBIO Inc. (RGNX) Q2 2021 Earnings Call Transcript
Revenue
$22.04M
▲ 33% YoY Diluted EPS
$-1.36
Gross margin
55.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
REGENXBIO Inc. (RGNX) Q1 2021 Earnings Call Transcript
Revenue
$18.88M
▲ 7% YoY Gross margin
74.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-05
REGENXBIO Inc. (RGNX) Q4 2020 Earnings Call Transcript
Revenue
$21.45M
▲ 82.2% YoY Diluted EPS
$-1.24
Gross margin
52.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-04
REGENXBIO Inc. (RGNX) Q3 2020 Earnings Call Transcript
Revenue
$98.91M
▲ 572.9% YoY Diluted EPS
$0.23
Gross margin
82.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
REGENXBIO Inc. (RGNX) Q2 2020 Earnings Call Transcript
Revenue
$16.57M
▲ 110.2% YoY Diluted EPS
$-0.91
Gross margin
71.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
REGENXBIO Inc. (RGNX) Q1 2020 Earnings Call Transcript
Revenue
$17.64M
▲ 1895.9% YoY Diluted EPS
$-1.08
Gross margin
80.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–34 of 34 webcasts
Key facts
CIK
1590877
CUSIP
75901B107
13F (30d)
127 filings
113 filers
Visit website
Investor relations